Mevrometostat plus enzalutamide in metastatic castration-resistant

Trial
100%75%50%25%0%Jun 24Jun 25Jun 24 00:18 UTC • YES 44.0%Jun 24 00:18 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 15:21 UTC • YES 44.0%Jun 24 15:21 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 18:31 UTC • YES 44.0%Jun 24 19:10 UTC • YES 50.0%Jun 24 19:16 UTC • YES 55.3%Jun 24 19:16 UTC • YES 60.0%Jun 24 22:32 UTC • YES 64.1%Jun 24 22:34 UTC • YES 62.9%Jun 24 22:35 UTC • YES 61.9%Jun 24 22:35 UTC • YES 60.8%Jun 24 22:36 UTC • YES 59.8%Jun 24 22:37 UTC • YES 58.7%Jun 24 22:38 UTC • YES 57.6%Jun 24 22:39 UTC • YES 56.5%Jun 24 22:40 UTC • YES 55.4%Jun 25 12:00 UTC • YES 55.3%Jun 25 15:55 UTC • YES 55.3%Jun 25 15:56 UTC • YES 55.3%Jun 25 16:02 UTC • YES 55.3%
ResolvedYES
Oracle Evidence
Medical illustration of prostate cancer with bone-metastasis context

Metastatic castration-resistant prostate cancer

Metastatic castration-resistant prostate cancer has spread and keeps growing despite very low testosterone. Delaying radiographic progression can mean the cancer stays controlled longer on scans.

1Most common cancer: No. 1 in U.S. men2Lifetime risk: About 1 in 8 men3Distant-stage survival: 38% at 5 years